Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 920-929

  Larsen, Sanne Bøjet ^a   Grove, Erik Lerkevang ^a   Kristensen, Steen Dalby ^a,b   Hvas, Anne Mette ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Aspirin; C reactive protein; Coronary artery disease; Inflammation; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYCLOOXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MULTIPLATE; PADGEM PROTEIN; THROMBOXANE B2; UNCLASSIFIED DRUG; VERIFYNOW;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HEMATOLOGY; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PLATELET REACTIVITY; PRIORITY JOURNAL; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 1; DRUG RESISTANCE; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LINEAR MODELS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK FACTORS; THROMBOXANE B2; TREATMENT OUTCOME;

EID: 84877032103     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-09-0666     Document Type: Article

References (26)

1. Arbab-Zadeh A, Nakano M, Virmani R, et al. Acute coronary events. Circulation 2012; 125: 1147-1156.
2. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
4. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
5. Battistoni A, Rubattu S, Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol 2012; 157: 160-168.
6. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
7. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc 2001; 286: 2107-2113.
8. Bernlochner I, Steinhubl S, Braun S, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010; 104: 1193-1200.
9. Ge H, Zhou Y, Liu X, et al. Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty. Angiology 2012; 63: 62-66.
10. Geisler T, Mueller K, Aichele S, et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol 2010; 99: 743-752.
11. Gori AM, Cesari F, Marcucci R, et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009; 202: 255-262.
12. Muller K, Aichele S, Herkommer M, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010; 213: 256-262.
13. Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol 2011; 58: 2630-2639.
14. Schmidt M, Maeng M, Jakobsen CJ, et al. Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clin Epidemiol 2010; 2: 137-144.
15. Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
16. Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185-191.
17. Patrono C, Rocca B. Drug insight: aspirin resistance--fact or fashion? Nat Clin Pract Cardiovasc Med 2007; 4: 42-50.
18. Hanriot D, Bello G, Ropars A, et al. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost 2008; 99: 558-569.
19. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101: 1785-1791.
20. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
21. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl 1): S13-S33.
22. Wang J, Zhang S, Jin Y, et al. Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol 2007; 115: 361-365.
23. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-495.
24. Grove EL, Storey RF, Wurtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012; 18: 5344-5361.
25. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-1713.
26. Gremmel T, Perkmann T, Seidinger D, et al. Differential Impact of Inflammation on Five Laboratory Assays Detecting Aspirin Resistance. Circulation 2011; 124: A12698.